Is There a Smart Path to Regulating Laboratory Developed Tests?
Xifin’s CEO sees a window of opportunity for lawmakers to modify the Final Rule on LDTs that will be a win-win for the industry and patients.
Category: Compliance
Compliance
Latest
Compliance
Latest
Is There a Balancing Point for LDT Regulations?
CLP Editor Chris Wolski examines the need for LDT regulations, and issues an industry-wide call to action.
Compliance
Latest
Stop the VALID Act, AMP Urges
AMP is urging medical organizations to contact their elected officials to remove the VALID Act from a 2023 "omnibus" appropriations bill.
Do Laboratory-Developed Tests Have a Future?
As the bipartisan VALID Act moves closer to a vote, the potential regulation could impact the future of laboratory-developed tests (LDTs).
Read More
CAP Files Amicus Brief in Support of No Surprises Act Lawsuit
The College of American Pathologists warns the No Surprises Act will further drive more physicians out of their patients’ health plan networks.
Read More
Accelerator Facility Launched for Clinical Lab Tests
To help diagnostics start-ups from around the world more rapidly enter the U.S. market, 20/20 GeneSystems is giving access to a CLIA laboratory.
Read More
FDA Response to COVID Gives Insights for Regulatory Future of LDTs
Certain temporary deviations in FDA policy in response to the COVID-19 pandemic may offer a blueprint for regulatory oversight of LDTs.
Read More
FDA Warns of Potential for False Positives with Roche Cobas SARS-CoV-2 and Influenza Test
Roche Molecular Systems’ cobas SARS-CoV-2 and Influenza A/B Nucleic Acid Test is for use on the cobas Liat System. The false positive results may be related to two issues observed by Roche.
Read More
Helmer i.C3 Download Functionality Supports Clinical Laboratory Compliance
The i.C3 monitors the temperature inside a laboratory refrigerator or freezer and activates alarms if the temperature rises or falls outside of the acceptable range.
Read More
COLA Launches Toolkit for Waived Laboratories
COLA’s Waived Testing Toolkit provides guidance and tools to help staff achieve and maintain waived testing excellence, including guidance on covid-19 reporting.
Read More
FDA Issues New Policy for Evaluating the Impact of Viral Mutations on Covid-19 Tests
The new guidances for medical product developers, specifically covering vaccines, diagnostics, and therapeutic products, address the emergence and potential future emergence of variants of SARS-CoV-2, the virus that causes covid-19.
Read More
MedTrainer Introduces LabComply to Simplify Lab Compliance
LabComply manages laboratory safety, administrative and engineering controls, training, documentation, and reporting as part of MedTrainer’s all-in-one healthcare compliance solution.
Read More
FDA Issues Alert to Clinical Laboratory Staff Regarding SARS-CoV-2 Viral Mutation
The FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests.
Read More
Webinar: Solving Confusion with Regulations, QC Design, and Troubleshooting for SARS CoV-2 Assays
The webinar, sponsored by Technopath, will cover quality control regulations, setting the proper QC strategy/design, and troubleshooting SARs CoV-2 and other semi-qualitative tests in the laboratory.
Read More
FDA Updates Serology Templates for Covid-19 Test Developers
The two new templates offer recommendations on what to include in emergency use authorization requests for serology tests.
Read More
From the Commissioner: FDA’s Ongoing Commitment to Transparency for Covid-19 EUAs
I want to take a moment to reaffirm FDA’s commitment to transparency around the EUA process and share some updates on our plan to provide more information about FDA’s decisions to issue, revise or revoke EUAs for drugs and biological products, including vaccines.
Read More
FDA Updates FAQs on Testing for Covid-19
The changes make it easier to navigate to questions by topic.
Read More
FDA Issues New Enforcement Policy for Modifications to FDA-Cleared Molecular Influenza and RSV Tests
The FDA has issued and immediately implemented a new guidance: Enforcement Policy for Modifications to FDA-Cleared Molecular Influenza and RSV Tests During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency.
Read More